RCS - SymBio Pharma - Edison issues ADR update - SymBio Pharmaceuticals <Origin Href="QuoteRef">4582.T</Origin>

SymBio PharmaceuticalsAnnouncement

05/01/2016 13:55

RNS Number : 5673H
SymBio Pharmaceuticals Limited
01 December 2015
London, UK, 1 December 2015
Edison issues ADR research update on SymBio Pharmaceuticals
SymBio recently acquired the exclusive rights to develop and market IONSYS, a fentanyl iontophoretic transdermal system for acute post-operative pain, in Japan. Treakisym is nearing a decision on additional indications and development is again moving ahead for rigosertib. With a third product in its development portfolio, we believe SymBio has the confidence to accelerate its in-licensing program on its quest to become the pharmaceutical partner of choice in Asia-Pacific.
SymBio Pharmaceuticals is a Japanese specialty pharma company with a focus on oncology, haematology and pain management. Treakisym was in-licensed from Astellas in 2005. Rigosertib was in-licensed from Onconova and IONSYS was in-licensed from The Medicines Company.

Click here to view the full report 
All reports published by Edison are available to download free of charge from its website. www.edisoninvestmentresearch.com
About Edison: We are an international equity advisory firm. We enable our client companies to achieve their capital market objectives. The team is made up of more than 80 analysts and investment professionals with many decades of experience. Our extensive company knowledge and industry expertise spans 10 business sectors and more than 700 listed companies globally. We give our corporate clients and investors privileged insight into global investment trends. Our distribution capability is key to ensuring that a global investor audience can access our investment knowledge. Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details:Learn more atwww.edisongroup.com and connect with Edison on: 
LinkedIn
www.linkedin.com/company/edison-investment-research
Twitter
www.twitter.com/Edison_Inv_Res
YouTube
www.youtube.com/edisonitv
Google+
https://plus.google.com/105425025202328783163/posts

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRAPKDDNDBDDCBK